EpiDestiny
https://www.epidestiny.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EpiDestiny
Novo Nordisk Boosts Specialty R&D With Kidney Disease Deal
Denmark's diabetes specialty company has linked up with a US biotech to evaluate a lysophosphatidic acid receptor antagonist in diabetic and chronic kidney disease.
Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought
But elephant in the room – the coming stream of readouts from Phase III PIONEER trials on oral semaglutide in Type 2 diabetes – gets little mention at first-quarter update.
Deals Shaping the Medical Industry (09/2011)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Deals Shaping the Medical Industry (06/2011)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals